Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cabozantinib in Patients With Advanced Osteosarcomas and Ewing sarcomas: a French Sarcoma Group (FSG)/ US National Cancer Institute phase II collaborative study.

Date

19 Oct 2018

Session

Proffered paper session - Sarcoma

Presenters

Antoine Italiano

Authors

A. Italiano1, N. Penel2, M. Toulmonde3, E. Bompas4, S. Piperno-Neumann5, M. Pulido6, N. Entz-Werle7, A. Le Cesne8, C.M. Chevreau9, F. Duffaud10, I.L. Ray-Coquard11, C. Bellera12, S. Mathoulin-Pelissier13, J. Blay14

Author affiliations

  • 1 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 2 General Oncology Department, Centre Oscar Lambret, 59020 - Lille/FR
  • 3 Medical Oncology, Institute Bergonié, 33076 - Bordeaux/FR
  • 4 Medicine, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 5 Medecine, Institut Curie, 75248 cedex5 - Paris/FR
  • 6 Epidemiological And Clinical research Unit And Inserm Cic1401, Institute Bergonié, Bordeaux/FR
  • 7 Pediatric Oncology, CHU STRASBOURG, 67000 - STRASBOURG/FR
  • 8 Department Of Medicine, Gustave Roussy, University Paris-Saclay, 94800 - Villejuif/FR
  • 9 31, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 10 Department Of Oncology, CHU La Timone Adultes, 13385 - Marseille/FR
  • 11 Medical Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 12 Clinical And Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, 33076 - BORDEAUX/FR
  • 13 Bordeaux University, Inserm Cic1401 And Clinical And Epidemiological Research Unit, Institut Bergonié, 33000 - Bordeaux/FR
  • 14 Medicine, Centre Léon Bérard, 69008 - Lyon/FR
More

Resources

Background

The prognosis of relapsed and unresectable high-grade osteosarcoma (OS) and Ewing sarcoma (ES) is dismal and unchanged over the last decades. There are no approved drugs in this setting. Pharmacologic inhibition of Met signaling and of aberrant angiogenesis has shown promising results in in several preclinical models of OS and ES.

Methods

These are 2 multicentre single-arm 2-stage phase 2 trials assessing efficacy and safety of cabozantinib in patients (pts) with advanced OS or ES. Pts receive cabozantinib (oral route, adults: 60 mg, children: 40 mg/m²), daily until progressive disease (PD) or unacceptable toxicity. For OS, the primary endpoint is a dual one based on 6-month objective response (OR) and non-progression. Assuming 25% 6-month non-PD (H0), 50% acceptable 6-month non-PD (H1); 5% OR (H0), 20% OR (H1); 5% type I error, 90% power, 41 assessable pts are necessary. The study will be considered as positive if at least 5 patients have OR or 16 patients are progression-free at 6 months. For ES, the primary endpoint is OR. Assuming 5% OR (H0), 20% OR (H1); 5% type I error, 90% power, 41 assessable pts are necessary. The study will be considered as positive if at least 5 patients have OR. Accrual started in 03/2015 in 15 centers of the FSG.

Results

90 pts (45 OS and 45 ES) were included. At the time of statistical analysis, 42 pts with OS and 33 pts with ES were eligible and evaluable for the 1st endpoint after central histological and radiological review. Median age was 34.5 (13–74) and 33 y (13–60) in the OS and ES cohorts respectively. The median number of previous lines of was 3 (1-7) and 4 (1-7) in the OS and ES cohorts respectively. 72 pts (96.0%) had at least one adverse event. 19 OS pts (45.2%) had tumor shrinkage: 5 (11.9%) with partial response (PR) and 14 (33.3%) with stable disease (SD). 19 ES pts (57.6%) had tumor shrinkage: 9 (27.7%) with PR and 10 (30.3%) with SD. 14 OS pts (33.3%) and 8 ES pts (24.2%) were progression-free at 6 months.

Conclusions

Cabozantinib has shown meaningful clinical activity in OS and ES patients with heavily pre-treated advanced disease and reached the primary endpoint of efficacy in both OS and ES cohorts Final efficacy and safety data will be presented at the meeting.

Clinical trial identification

NCT02243605

Editorial Acknowledgement

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings